Eric Sullivan

Eric Sullivan is an accomplished financial executive with extensive experience in the biotechnology sector. Currently serving as Chief Financial Officer at Convergent Therapeutics, Inc. since September 2023, Eric also holds a position on the Board of Directors for Chimeric Therapeutics, where Eric chairs the Audit & Risk Committee and is a member of the Remuneration & Nomination Committee. Previously, Eric was Chief Financial Officer at TCR² Therapeutics Inc. until its acquisition by Adaptimmune in June 2023 and held similar CFO and COO roles at Triplet Therapeutics from 2019 to 2022. Other notable positions include Senior Vice President of Finance at Gemini Therapeutics, SVP of Finance & Operations at Oncorus, and VP of Finance, Treasurer, and Principal Accounting Officer at bluebird bio. Eric's career began at PwC as an Audit Manager, following a role as Corporate Controller at Merrimack. Eric holds a degree from Bentley University.